Effects of Aripiprazole on Cocaine Craving and Self-Administration

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate whether aripiprazole will decrease cocaine self-administration, subjective effects and cravings compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Aripiprazole; Cocaine

Criteria

Inclusion Criteria:

• Meets DSM-IV criteria for current cocaine abuse

• Average use of smoked cocaine is at least 2x/week for past 6 mos); currently spends at least $70 per week on cocaine

• Has patterns of smoked cocaine use in terms of frequency and amounts which parallel or exceed those administered in the study

• Age 21-45

• Able to give informed consent, and comply with study procedures

Exclusion Criteria:

• Current seizure disorder, heart disease or psychiatric disorders (other than cocaine dependence)

• Dependence on substances other than cocaine or nicotine

• Request for drug treatment

• Judged to be noncompliant with study protocol

• Current use of any medication that has the potential to interact with aripiprazole (i.e., seizure medications, anti-fungal medications, cardiac medications, or medication that produces drowsiness)

• Clinical laboratory tests outside normal limits that are clinically unacceptable to the study physician (BP > 140/90; BUN, creatinine, LFTs > 1.5 ULN; hematocrit < 34 for women, < 36 for men; pseudocholinesterase deficiency)

• Currently meeting DSM-IV criteria for all major psychiatric/psychotic disorders other than transient psychosis due to drug abuse

• Current parole or probation

• History of significant violent or suicidal behavior